NRF1 and Miyoshi myopathy: These findings suggest that the suppression of proteasomes by proteasome inhibitors is insufficient as an effective MM therapy due to the NRF1-mediated recovery of proteasomes, called the bounce-back response of proteasome, in MM tissues [10,11,12].